Harrow Health, Inc. (HROW) NASDAQ
32.95
-1.16(-3.40%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
32.95
-1.16(-3.40%)
Currency In USD
| Previous Close | 34.11 |
| Open | 33.96 |
| Day High | 34.65 |
| Day Low | 32.86 |
| 52-Week High | 54.85 |
| 52-Week Low | 27.76 |
| Volume | 460,693.04 |
| Average Volume | 870,211 |
| Market Cap | 1.23B |
| PE | -86.71 |
| EPS | -0.38 |
| Moving Average 50 Days | 36.28 |
| Moving Average 200 Days | 41.33 |
| Change | -1.16 |
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
GlobeNewswire Inc.
Mar 04, 2026 12:00 PM GMT
NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner’s 2026 Global Healthcare Con
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
GlobeNewswire Inc.
Mar 03, 2026 12:00 PM GMT
NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigatio
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
GlobeNewswire Inc.
Feb 18, 2026 12:00 PM GMT
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,